Welcome to our dedicated page for Jaguar Health news (Ticker: JAGX), a resource for investors and traders seeking the latest updates and insights on Jaguar Health stock.
Jaguar Health Inc (NASDAQ: JAGX) delivers innovative plant-based therapeutics for gastrointestinal health across human and animal populations. This news hub provides investors and healthcare professionals with essential updates about the company’s clinical developments, regulatory milestones, and sustainable pharmaceutical innovations.
Access official press releases and verified news covering key areas including FDA approvals for Mytesi® (crofelemer), veterinary health product developments like Canalevia™, clinical trial progress, and strategic partnerships. Our curated collection ensures timely updates on JAGX’s advancements in non-opioid anti-secretory treatments and ecological sourcing practices.
Discover updates across multiple categories: new product launches, research collaborations, financial disclosures, intellectual property developments, and sustainability initiatives. Each update is vetted for accuracy, providing reliable insights into Jaguar Health’s progress in addressing chronic diarrhea conditions and neglected gastrointestinal disorders.
Bookmark this page for streamlined access to Jaguar Health’s latest developments. Check back regularly for updates on their unique approach to combining traditional botanical knowledge with modern pharmaceutical science through subsidiaries like Napo Pharmaceuticals.
Jaguar Health (Nasdaq:JAGX) announced that enrollment in its pivotal Phase 3 OnTarget clinical trial of crofelemer has surpassed 90%, with completion expected by mid-Q2 2023. This trial aims to assess the effectiveness of crofelemer in preventing diarrhea in adult cancer patients undergoing targeted therapy. The company’s current cash position stands at approximately $15.3 million. The OnTarget trial, now expanded to include sites in Eastern Europe, Argentina, and Taiwan, is crucial in demonstrating that chronic diarrhea affects patient adherence to cancer therapies. The trial evaluates crofelemer’s unique mechanism of action, targeting chloride ion channels in the gastrointestinal tract.
FAQ
What is the current stock price of Jaguar Health (JAGX)?
What is the market cap of Jaguar Health (JAGX)?
